Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Mallinckrodt
McKinsey
Johnson and Johnson

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR HALAVEN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Halaven

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00365157 ↗ Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2006-10-23 This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.
NCT00410553 ↗ Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery Completed National Cancer Institute (NCI) Phase 1 2006-11-14 This phase I trial is studying the side effects and best dose of eribulin mesylate and gemcitabine hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as eribulin mesylate and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
NCT01372579 ↗ Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Unknown status Eisai Inc. Phase 2 2011-08-01 This phase II trial studies how well giving eribulin mesylate and carboplatin together before surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
NCT01372579 ↗ Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Unknown status Northwestern University Phase 2 2011-08-01 This phase II trial studies how well giving eribulin mesylate and carboplatin together before surgery works in treating patients with stage I-III triple-negative breast cancer. Drugs used in chemotherapy, such as eribulin mesylate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
NCT01388647 ↗ Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer Terminated Eisai Inc. Phase 1/Phase 2 2011-08-01 This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically stage IIA to IIIB. The study regimen will be administered every 3 weeks for a total of 6 cycles followed by definitive surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Halaven

Condition Name

Condition Name for Halaven
Intervention Trials
Breast Cancer 16
Metastatic Breast Cancer 12
Liposarcoma 3
Metastatic Urothelial Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Halaven
Intervention Trials
Breast Neoplasms 44
Carcinoma 8
Triple Negative Breast Neoplasms 8
Carcinoma, Transitional Cell 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Halaven

Trials by Country

Trials by Country for Halaven
Location Trials
United States 250
Spain 13
Canada 11
India 10
France 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Halaven
Location Trials
Florida 14
Texas 13
Missouri 11
Georgia 10
California 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Halaven

Clinical Trial Phase

Clinical Trial Phase for Halaven
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2 35
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Halaven
Clinical Trial Phase Trials
Completed 19
Recruiting 14
Active, not recruiting 10
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Halaven

Sponsor Name

Sponsor Name for Halaven
Sponsor Trials
Eisai Inc. 18
National Cancer Institute (NCI) 11
Dana-Farber Cancer Institute 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Halaven
Sponsor Trials
Other 57
Industry 41
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Colorcon
Harvard Business School
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.